Dr. rer. nat. Pierre Tannig

Dr. Pierre Tannig holds a degree in molecular science and was admitted as a German Patent Attorney, European Patent Attorney and European Trademark and Design Attorney in 2024.

Dr. Pierre Tannig has been working in the field of intellectual property since 2020. After completing his training at a patent law firm in Erlangen and working for renowned patent law firms in Munich, Dr. Tannig joined the law firm Wallinger Ricker Schlotter Tostmann in 2024.

His practice focuses on drafting patent applications and conducting European patent prosecution and opposition proceedings as well as preparing FTO opinions.

Dr. Tannig completed his studies in molecular science at the Friedrich-Alexander-University Erlangen-Nuremberg with a focus on medicinal chemistry, molecular biology and virology. During his doctorate at the Virological Institute of the University Hospital Erlangen in the working group of Prof. Dr. Klaus Überla, he focused on developing a vaccination strategy to optimize the vaccine-induced immune response against the human immunodeficiency virus (HIV). In addition, he co-developed a peptide-based method to immobilize the HIV surface protein on liposomes.

Due to his background, Dr. Tannig has a broad technical expertise: inorganic chemistry, organic chemistry, pharmacy, molecular biology, biotechnology, immunology and virology.

since 2024
Patent attorney at Wallinger Ricker Schlotter Tostmann
Admitted as German Patent Attorney, European Patent Attorney and European Trademark and Design Attorney

since 2020
Active in the field of intellectual property
Training as a patent attorney at a patent law firm in Erlangen, the German Patent and Trademark Office and the Federal Patent Court

2016 - 2020
Research Fellow at the Institute for Clinical and Molecular Virology at the University Hospital Erlangen

2014 - 2016
Studies of Molecular Sciences with a focus on virology at the Friedrich-Alexander-University Erlangen Nuremberg (M.Sc.)

2011 - 2014
Study of Molecular Science with specialization in Molecular Life Science at the Friedrich-Alexander-University Erlangen Nuremberg (B.Sc.)
 

• Patentanwaltskammer (PAK)
• Institut der beim Europäischen Patentamt zugelassenen Vertreter (epi)

• Oriented Display of HIV-1 Env Trimers by a Novel Coupling Strategy enhances B Cell Activation and Phagocytosis.
  Riccardo Di Vincenzo, Jannis Beutel, Philipp Arnold, Yu Wang, Dominik Damm, Pierre Tannig, Anja Lux, Vladimir Temchura, Jutta Eichler, Klaus Überla. Frontiers in Immunology, 2024, 15:1344346. doi: 10.3389/fimmu.2024.1344346
• Bind&Bite: Covalently stabilized heterodimeric coiled-coil peptides for the site-selective, cysteine-free chemical modification of proteins.
  Jannis Beutel, Pierre Tannig, Riccardo Di Vincenzo, Thomas Schumacher, Klaus Überla, Jutta Eichler. RSC Chemical Biology. 2023, 4, 794-803. doi: 10.1039/d3cb00122a
• CD4+ T Cells Induced by Tuberculosis Subunit Vaccine H1 Can Improve the HIV-1 Env Humoral Response by Intrastructural Help. 
  Stephan Klessing, Vladimir Temchura, Pierre Tannig, Antonia Sophia Peter, Dennis Christensen, Roland Lang, Klaus Überla. Vaccines (Basel). 2020 Oct 13;8(4):604. doi: 10.3390/vaccines8040604. PMID: 33066267; PMCID: PMC7711721.
• Genetic Co-Administration of Soluble PD-1 Ectodomains Modifies Immune Responses against Influenza A Virus Induced by DNA Vaccination. 
  Pierre Tannig, Antonia Sophia Peter, Dennis Lapuente, Stephan Klessing, Anna Schmidt, Dominik Damm, Matthias Tenbusch, Klaus Überla, Vladimir Temchura. Vaccines (Basel). 2020 Oct 1;8(4):570. doi: 10.3390/vaccines8040570. PMID: 33019546; PMCID: PMC7712647.
• The trimeric artesunate derivative TF27 exerts strong anti-cytomegaloviral efficacy: Focus on prophylactic efficacy and oral treatment of immunocompetent mice. 
  Markus Wild, Luca D. Bertzbach, Pierre Tannig, Christina Wangen, Regina Müller, Lars Herrmann, Tony Fröhlich, Svetlana B. Tsogoeva, Benedikt B. Kaufer, Manfred Marschall, Friedrich Hahn. Antiviral Res. 2020 Jun; 178:104788. doi: 10.1016/j.antiviral.2020.104788. Epub 2020 Apr 3. PMID: 32251769.
• Patterns of Autologous and Nonautologous Interactions Between Core Nuclear Egress Complex (NEC) Proteins of α-, β- and γ-Herpesviruses. 
  Sigrun Häge, Eric Sonntag, Eva Maria Borst, Pierre Tannig, Lisa Seyler, Tobias Bäuerle, Susanne M. Bailer, Chung-Pei Lee, Regina Müller, Christina Wangen, Jens Milbradt, Manfred Marschall. Viruses. 2020 Mar 11;12(3):303. doi: 10.3390/v12030303. PMID: 32168891; PMCID: PMC7150769.
• Modulation of Vaccine-Induced HIV-1-Specific Immune Responses by Co-Electroporation of PD-L1 Encoding DNA. 
  Pierre Tannig, Antonia Sophia Peter, Dennis Lapuente, Stephan Klessing, Dominik Damm, Matthias Tenbusch, Klaus Überla, Vladimir Temchura. Vaccines (Basel). 2020 Jan 14;8(1):27. doi: 10.3390/vaccines8010027. PMID: 31947643; PMCID: PMC7157229.
• In vivo proof-of-concept for two experimental antiviral drugs, both directed to cellular targets, using a murine cytomegalovirus model. 
  Eric Sonntag, Friedrich Hahn, Luca D. Bertzbach, Lisa Seyler, Christina Wangen, Regina Müller, Pierre Tannig, Benedikt Grau, Matthias Baumann, Eldar Zent, Gunther Zischinsky, Jan Eickhoff, Benedikt B. Kaufer, Tobias Bäuerle, Svetlana B. Tsogoeva, Manfred Marschall. Antiviral Res. 2019 Jan; 161:63-69. doi: 10.1016/j.antiviral.2018.11.008. Epub 2018 Nov 17. PMID: 30452929.